Callicutt W. Jack's most recent trade in Galectin Therapeutics Inc was a trade of 65,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 23, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
Galectin Therapeutics Inc | W. Callicutt Jack | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 47,614 (0%) | 0% | 0 | Common Stock | |
Galectin Therapeutics Inc | W. Jack Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 23 Dec 2024 | 40,000 | 7,614 (0%) | 0% | 0.9 | 35,492 | Common Stock |
Galectin Therapeutics Inc | Callicutt W. Jack | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 0 | - | - | Restricted Stock Units | |
Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
Galectin Therapeutics Inc | W. Callicutt Jack | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 40,000 | 40,000 | - | - | Restricted Stock Unit | |
Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.32 per share. | 17 Nov 2022 | 4,000 | 7,614 (0%) | 0% | 1.3 | 5,280 | Common Stock |
Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 100,000 | 100,000 | - | - | Stock option (right to buy) | |
Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 50,000 | 50,000 | - | - | Stock option (right to buy) |